Skip to content
Sensei Biotherapeutics
Clinical-Stage Biotechnology
Sensei Biotherapeutics
  • About
  • Pipeline
    • Overview
    • SNS-301
    • SNS-401
    • Vista
    • Presentations
  • Platform
    • Immunophage
    • Therapeutic cocktails
    • Immunophage + Nanobodies
    • GMP Manufacturing
    • Publications
  • Our Leadership
    • Senior Leadership
    • Board Of Directors
    • Immuno Oncology Advisory Board
  • News
    • Press Releases
  • Careers
Contact
  • About
  • Pipeline
    • Overview
    • SNS-301
    • SNS-401
    • Vista
    • Presentations
  • Platform
    • Immunophage
    • Therapeutic cocktails
    • Immunophage + Nanobodies
    • GMP Manufacturing
    • Publications
  • Our Leadership
    • Senior Leadership
    • Board Of Directors
    • Immuno Oncology Advisory Board
  • News
    • Press Releases
  • Careers

Publications

Iwagami Y et al. Lambda phage-based vaccine induces antitumor immunity in hepatocellular carcinoma. Heliyon. 2017, PMID: 28971150

PublicationDecember 12, 2020
Details

Arab A et al. Lambda phage nanoparticles displaying HER2-derived E75 peptide induce effective E75-CD8+ T response. Immunol Res. 2018, PMID: 29143917

PublicationDecember 12, 2020
Details

Razazan A et al. Lambda bacteriophage nanoparticles displaying GP2, a HER2/neu derived peptide, induce prophylactic and therapeutic activities against TUBO tumor model in mice. Sci Rep. 2019, PMID: 30778090

PublicationDecember 12, 2020
Details

Ghaemi A et al. Recombinant lambda-phage nanobioparticles for tumor therapy in mice models. Genet Vaccines Ther. 2010, PMID: 20459865

PublicationDecember 12, 2020
Details

Bartolacci C, et al. Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer [published correction appears in Cancer Immunol Res. 2019, PMID: 30327365

PublicationDecember 12, 2020
Details

Burtness B, et al. KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019, PMID: 31679945

PublicationDecember 12, 2020
Details

Ferris RL et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016, PMID: 27718784

PublicationDecember 12, 2020
Details

Mehra R et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer. 2018 Jul, PMID: 29955135

PublicationDecember 12, 2020
Details

Ulivieri C et al. Antigenic properties of HCMV peptides displayed by filamentous bacteriophages vs. synthetic peptides. Immunol Lett. 2008, PMID: 18538862

PublicationDecember 12, 2020
Details

Sartorius R et al. Antigen delivery by filamentous bacteriophage fd displaying an anti-DEC-205 single-chain variable fragment confers adjuvanticity by triggering a TLR9-mediated immune response. EMBO Mol Med. 2015, PMID: 25888235

PublicationDecember 12, 2020
Details
12
Blog Topics
  • Featured(1)
  • Presentation(3)
  • Press Release(24)
  • Publication(16)
  • Recent(1)
Recent Posts
  • Sensei Biotherapeutics Announces $30 Million Financing to Advance Clinical Pipeline of Oncology Therapeutics and Proprietary ImmunoPhage™ Platform
  • SITC Safety and Efficacy
  • Refractory Head and Neck Cancer Enrollment Update
  • SITC TIP
  • Iwagami Y et al. Lambda phage-based vaccine induces antitumor immunity in hepatocellular carcinoma. Heliyon. 2017, PMID: 28971150
About

We are a clinical-stage immunotherapy company engaged in the discovery and development of next generation therapies with an initial focus on treatments for cancer. Our proprietary ImmunoPhage platform is a powerful, self-adjuvanted and highly differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response.

Contact
Headquarters
1405 Research Blvd, Suite 125
Rockville, MD 20850
Phone No
phone

+1.240.243.8000

Boston R&D Location
Smart Labs, Seaport District
6 Tide Street
Boston, MA 02210
Email
phone

info@senseibio.com

© 2021 Sensei Biotherapeutics. All Rights Reserved.
  • Privacy Policy
Footer
Go to Top